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Objective. To investigate the clinicopathological characteristics of gastrointestinal stromal tumor (GIST) with significant cystic
changes and to assess the molecular genetic characteristics. Methods. In a 68-year-old man, a large abdominal tumoral mass was
discovered incidentally. Computed tomography (CT) and magnetic resonance imaging (MRI) confirmed the presence of a large
cystic lesion with multiple contrast-enhancing septae and papillary projections. No clear connection with any of the surrounding
organs was identified. Malignancy could not be excluded, and surgery was indicated. During surgery, the large mass was found to
be attached by a narrow stalk to the large curvature of the stomach. Results. The histological features and immunohistiochemical
profile of the tumor cells (positivity for CD117 and CD34) were consistent with a gastrointestinal stromal tumor with a high risk
of progressive disease according to the Fletcher classification. Diagnosis was confirmed by mutational analysis; this demonstrated
mutation in exon 14 of PDGFRA. During the followup of 97 months, the patient had a cancer-free survival. Conclusions. This
case demonstrates that gastrointestinal stromal tumors (GISTs) with extensive cystic degeneration should be considered in the
diﬀerential diagnosis of a cystic abdominal mass.
1. Introduction
Gastrointestinal stromal tumors (GISTs) are specific mes-
enchymal tumors of the gastrointestinal tract. GISTs are rare,
accounting for only 0.2% of all gastrointestinal tumors [1].
Morphologically they show similarities to other tumor types
and were previously misclassified as leiomyomas, leiomy-
oblastomas, or leiomyosarcomas, but also as schwannomas
or malignant peripheral nerve sheath tumors. Since the
discovery of KIT (CD117) in 1998, GISTs were identified as
a distinct entity [2]. These tumors are believed to originate
from the interstitial cells of Cajal or related stem cells [3–
6]. Proper identification of GIST has become very important
since the availability of a specific pathogenesis-targeted
treatment, namely, imatinib. GISTs usually present as solid
tumors. We report an incidental finding of a cystic gastric
GIST with exophytic pedunculated growth.
2. Case Report
In a 68-year-old man, a large abdominal tumoral mass
was discovered incidentally during checkup for vascular
insuﬃciency of the lower limbs. The patient complained of
vascular insuﬃciency and had no symptoms of abdominal
pain. Physical examination revealed a palpable mass in the
right upper quadrant of the abdomen. Results of blood
samples were all within normal values.
Ultrasonography showed a well-defined large cystic
mass with several membranous septa with a diameter of
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Figure 1: Abdominal ultrasonography (US) showing a well-





Figure 2: Abdominal computed tomography (CT) displaying a
large cystic lesion (arrow) adjacent to the right liver lobe, the
stomach, and the pancreatic head.
approximately 12 cm in the right hypochondrium (Figure 1).
Subsequent computed tomography (CT) scan demonstrated
a large cystic lesion adjacent to the right liver lobe, the
stomach, and the pancreatic head (Figure 2). On MRI
imaging, markedly high intensity, compatible with cystic
nature, was revealed in the tumor. The tumor was lying
in contact with the right liver lobe, the stomach, and the
pancreatic head (Figure 3).
However, no clear connection with any of these organs
was identified. The imaging findings demonstrated no
vascularity of the lesion. Malignancy could not be excluded,
and surgery was indicated.
At laparotomy a large exophytic mobile mass was found
to be attached by a narrow stalk to the larger curvature of the
stomach at the level of the antrum. No infiltration into the
surrounding tissues was observed.
Cystic lesion
Liver
Figure 3: On MRI imaging markedly high intensity, compatible
with cystic nature (arrow), was revealed in the tumor.
Figure 4: Macroscopically, a large unilocular cystic tumor with a
smooth outer surface and several membranous septa projecting in
the lumen was found.
Surgical resection of the mass along with a wedge
resection of the stomach, at the larger curvature, adjoining
the stalk and the adherent omentum was performed.
The resected tumor measured almost 12 cm in diameter.
Grossly, it was a unilocular cystic tumor filled with serous
fluid, with a smooth outer surface and several membranous
septa projecting in the lumen (Figure 4). The cyst had a
thin wall. The stalk was connecting the cystic tumor with
the stomach. The mitotic activity was less than 5 mitoses
per 50 HPF. The tumor cells showed positivity for CD117
(KIT) and CD34. The histological features together with
the immunohistiochemical profile of the tumor cells were
consistent with a gastrointestinal stromal tumor (GIST) with
a high risk of progressive disease according to the Fletcher
classification. Molecular analysis of this tumor showed a
mutation in exon 14 of the PDGFRA gene (substitution exon
14, N659K). Since PDGFRA exon 14 mutant GIST is sen-
sitive to imatinib mesylate (Glivec), this oral treatment was
started postoperatively because the high risk of recurrence in
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this patient (high risk of progressive disease according to the
Fletcher classification). Untill now the patient is still free of
recurrence.
3. Discussion
Gastrointestinal stromal tumors (GISTs) are rare neoplasms,
with an annual incidence of approximately 4 per million
[3]. Historically, these tumors were classified as leiomyomas,
leiomyoblastomas, and leiomyosarcomas, because of a mis-
taken belief that they originated from smooth muscle in the
wall of the gastrointestinal tract [2].
The cellular origin of GIST recently has been proposed to
be the interstitial cell of Cajal, an intestinal pacemaker cell.
This postulate is supported by the finding that GISTs display
positivity for cell markers similar to those of the normal cell
of Cajal [4–6]. The majority (approximately 95%) of GISTs
express the CD117 antigen (KIT), a protooncogene product.
CD34, a commonly expressed human progenitor cell antigen,
is also frequently found positive in GISTs [3]. More than half
of the GISTs are located in the stomach followed, by the small
intestine, colon and rectum, and esophagus [1, 3, 7].
Complete tumor resection with disease-free resection
margins is the treatment of choice for primary nonmetastatic
tumors. Lymphadenectomy is not recommended because
lymph node involvement is rare. Wedge resection allows full-
thickness resection of the stomach wall containing the tumor,
with negative resection margins [1, 6].
Grossly, GISTs vary greatly in size and can be more than
30 cm in diameter. These tumors are usually well circum-
scribed and unencapsulated. GIST can grow in an endophytic
or exophytic pattern. They are usually solid. Small cysts are
frequently observed, presumably as a consequence of cystic
degeneration or necrosis. Larger stromal tumors usually
degenerate, and cysts are formed [8–11].
In the present case, the large size of the cyst obscured the
origin from the stomach. Imaging showed that the tumor
was not originating from the pancreas or any other organ,
so the exact origin of the tumor could not be determined
preoperatively. Imaging demonstrated no vascularity of the
lesion. Since malignancy could not be excluded in our case
and the origin of the tumor could not be determined by
imaging, surgery was indicated.
Complete tumor resection with disease-free resection
margins is the treatment of choice for primary nonmetastatic
tumors. Lymphadenectomy is not recommended because
lymph node involvement is rare. Wedge resection allows full-
thickness resection of the stomach wall containing the tumor,
with negative resection margins [1, 6].
Lesions that should be considered in the diﬀerential
diagnosis of a cystic abdominal mass on radiologic imaging
(CT and MRI) include gastric or bowel duplication cysts,
cystic mesothelioma, cystic lymphangioma, cystic mucinous
retroperitoneal tumors, cystic pancreatic tumors, pseudo-
cysts of the pancreas or peritoneum, cystic teratoma, and
GIST [12–14].
In this case, tumor cells showed diﬀuse and strong
positivity for CD117 (KIT) and CD34, which was consistent
with a diagnosis of GIST. This was confirmed by molecular
biology that showed a mutation in exon 14 of the PDGFRA
gene (exon 14 substitution, N659K).
Wang et al. recently published a series of 7 patients
with cystic GISTs and analysis of c-kit and PDGFRA gene.
Gene mutation of exon 11 of c-kit was identified in 3
cases [15]. PDGFRA mutant GISTs arise almost exclusively
in the stomach, whereas KIT mutant tumors occur at a
variety of sites along the gastrointestinal tract. PDGFRA
exon 14 mutations may be associated with a reduced risk of
recurrence. Limited clinical data are published, but PDGFRA
exon 14 mutant GISTs appear; sensitive to imatinib, the
sensitivity is similar to KIT exon 11 mutants [16–18].
In summary, GISTs with cystic appearance clearly should
be considered in the diﬀerential diagnosis of cystic abdom-
inal tumors. Most GISTs (95%) express Kit (CD117) and
CD34 (70%). In case of doubt genmutation analysis is
necessary. KIT and PDGFRA genotyping is important for
GIST diagnosis and assessment of sensitivity to tyrosine
kinase inhibitors.
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